SCHEDULE: Franklin Resources Discloses 9.4% Stake in IN8bio

Franklin Resources, Inc. and its affiliates have reported a 9.4% beneficial ownership stake in IN8bio, Inc. as of December 31, 2025.

Summary

• Franklin Resources, Inc. and its affiliates, including Franklin Advisers, Inc., collectively reported beneficial ownership of 914,531 shares of IN8bio, Inc. common stock.
• This represents 9.4% of IN8bio, Inc.'s outstanding common stock.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Warrants to purchase additional shares were excluded from the reported beneficial ownership to avoid exceeding a 4.99% ownership threshold for aggregated affiliates.
• Franklin Biotechnology Discovery Fund, a sub-fund of Franklin Templeton Investment Funds, holds an interest in 582,427 shares, representing 6.0% of the class.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional investor has disclosed a substantial passive stake in IN8bio, Inc., suggesting long-term confidence without immediate intent to influence management.

Positives

• A significant institutional investor, Franklin Resources, Inc., holds a substantial stake in IN8bio, Inc., potentially indicating confidence in the company.
• The filing explicitly states the stake is for ordinary course of business, not for control, suggesting a passive, long-term investment intent.

Risks

• No specific risks related to IN8bio, Inc.'s operations or financial health are disclosed in this beneficial ownership filing.

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into significant holdings by major investment firms. For a biotechnology company like IN8bio, Inc., a substantial stake from a prominent asset manager such as Franklin Resources can be viewed positively by the market, signaling a degree of validation for its long-term prospects, even if the investment is passive.

Comparison to Industry Standards

• A 9.4% stake by a major asset manager like Franklin Resources is a significant position, often exceeding typical initial passive stakes in smaller biotechnology companies.
• The explicit disclaimer of intent to influence control aligns with standard passive investment strategies for institutional funds, differentiating it from activist investor filings (Schedule 13D).
• The exclusion of warrants to maintain a beneficial ownership below 4.99% for aggregated affiliates demonstrates adherence to regulatory thresholds and reporting requirements, a common practice among large investment groups.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder; potential positive sentiment from market validation.
• Management: No direct impact on management or operations, as the stake is passive and not for control.

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment by Franklin Resources, Inc. in IN8bio, Inc. This suggests a degree of confidence from a major asset manager, which can be a positive long-term indicator. However, as a Schedule 13G, it does not provide new operational or financial performance data for IN8bio, Inc. to warrant a "buy" or "sell" recommendation. The "hold" recommendation reflects the neutral-to-slightly-positive signal of institutional backing without new fundamental information.

Keywords

IN8bio, Franklin Resources, Franklin Advisers, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology